GlassScriptPhysician profile
Aruna C Hulme
NPI 1952618332
$16,539.41
in general payments reported to CMS, 2019-2025
29 companies · $3,906 in 2025
The $3,906 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,237 · 2022: $2,573 · 2023: $3,526 · 2024: $4,298 · 2025: $3,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $5.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,724.52 |
| Education | $5.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,672.27 | 2021-2025 | |
| Alkermes, INC. | $2,465.97 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,872.26 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,309.86 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $1,138.43 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $1,129.13 | 2021-2025 | Rexulti, Abilify Mycite, Nuedexta |
| Neurocrine Biosciences, INC. | $1,090.33 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $780.71 | 2022-2025 | Auvelity, Sunosi |
| Corium, LLC | $667.29 | 2022-2025 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $629.59 | 2022-2025 | Qelbree, Qelbree |
| Bausch Health US, LLC | $416.61 | 2021-2025 | Wellbutrin, Aplenzin |
| Vanda Pharmaceuticals INC. | $390.34 | 2022-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $334.36 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $303.92 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $276.62 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $211.20 | 2024-2025 | Brixadi |
| Janssen Pharmaceuticals, INC | $181.98 | 2021-2022 | |
| Neos Therapeutics, LP | $177.52 | 2021-2025 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $159.24 | 2022-2024 | Quviviq |
| Astellas Pharma US INC | $66.28 | 2024 | Veozah |
| Indivior INC. | $61.71 | 2023-2025 | Sublocade |
| Acadia Pharmaceuticals INC | $33.90 | 2022-2025 | Nuplazid |
| Almatica Pharma LLC | $32.43 | 2022-2024 | Loreev Xr |
| Owp Pharmaceuticals, INC. | $28.35 | 2021 | |
| Ironshore Pharmaceuticals INC. | $27.88 | 2022-2023 | Jornay Pm |
| Eisai INC. | $23.79 | 2022 | |
| Tris Pharma INC | $22.34 | 2021 | |
| Livanova USA, INC. | $22.24 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Arbor Pharmaceuticals, INC. | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruna Hulme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.